BI 135585

Drug Profile

BI 135585

Alternative Names: B-135585; BI 135585 XX; BI-135585

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim; Vitae Pharmaceuticals
  • Developer Boehringer Ingelheim
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 22 Aug 2012 Boehringer Ingelheim initiates enrolment in a phase I trial in Healthy volunteers in Germany (NCT01652742)
  • 01 Apr 2012 BI 135585 is still in phase I trials for Type-2 diabetes mellitus
  • 27 Jul 2011 Boehringer Ingelheim completes enrolment in its phase I trial for Type-2 diabetes mellitus in Germany (NCT01282970)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top